![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 10, 2023
This phase 3 study is comparing the efficacy of intravesical chemotherapy after surgery to the usual approach of intravesical immunotherapy after surgery
February 10, 2023
These three trials are open and enrolling adults with multiple myeloma or at high risk of developing the disease
February 10, 2023
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
December 20, 2022
Some of the most memorable moments of the 10th Anniversary General Session featured three individuals who have been key participants and collaborators in ECOG-ACRIN’s research over the years
December 20, 2022
Funding and support are now available to sites to implement natural language processing for recruitment of patients to study EA2185
December 20, 2022
This phase 2 study is examining whether the addition of cisplatin to PORT will provide a survival benefit to certain patients with stage 3/4 squamous cell carcinoma of the head and neck
October 13, 2022
Health care administrator Charmaine Green shares her experience supporting cancer clinical trials and discusses how her role has evolved over the years
October 13, 2022
Eight early-career investigators will present their work; two will be selected to receive awards of distinction
October 13, 2022
This phase 3 study aims to explore whether treatment with a TKI plus blinatumomab may be superior to the usual treatment approach for acute lymphoblastic leukemia
October 13, 2022
A Standing Main Member of ECOG-ACRIN since 1983
October 13, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 16, 2022
Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation